Pharmacopoeia Compliance Series

September 18, 2019

In this series of articles, J. Mark Wiggins, owner and compendial consultant with Global Pharmacopoeia Solutions LLC, and Joseph A. Albanese, director of Analytical Strategy and Compliance at Janssen Research and Development, LLC, provide an understanding about the need for pharmacopoeia compliance.

In this series of articles, J. Mark Wiggins, owner and compendial consultant with Global Pharmacopoeia Solutions LLC, and Joseph A. Albanese, director of Analytical Strategy and Compliance at Janssen Research and Development, LLC, provide an understanding about the need for pharmacopoeia compliance.

The following articles can be found within this series:

Why Pharmacopoeia Compliance is Necessary

View HTML

View PDF

Why Pharmacopoeia Compliance is Difficult

View HTML

View PDF

A Brief History of Pharmacopoeias: A Global Perspective

View HTML

Global Pharmacopoeia Standards: Why Harmonization is Needed

View HTML

View PDF

Harmonization Efforts by Pharmacopoeias and Regulatory Agencies

View HTML

Revision Process for Global/National PharmacopoeiasView HTMLView PDF
Surveillance Process for Industry: Monitoring Pharmacopoeia RevisionsView HTML
Monograph Development: Why and When to ParticipateView HTML
Monograph Development: How to Participate; How to HarmonizeView HTML
A Practical Approach to Pharmacopoeia ComplianceView HTML
A Case Study in Pharmacopoeia Compliance: Excipients and Raw MaterialsView HTML
Pharmacopoeia Compliance: Putting it All Together; What is on the HorizonView HTML

 

 

Related Content:

Compendial Compliance